Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

The Kennedy Trust logo

The scheme will fund 15 students a year for 5 years, 4 of whom will be in Oxford. The other successful Universities Birmingham, Manchester and Glasgow/Edinburgh. The scheme follows the successful launch this year of a BM DPhil educational training program in cancer studies funded by CRUK. Students will be hosted within the Medical Sciences Doctoral training program.

Professor Paul Bowness, Professor of Experimental Rheumatology who led the application, said: "Oxford is thrilled to join the Kennedy Trust MB PhD scheme. This scheme will provide a unique opportunity to educate a new generation of clinician scientists, harnessing Oxford's established research strengths. We are confident these doctors will lead research for the benefit of patients with musculoskeletal diseases many years to come."

Professor Sir Stephen Holgate, The Kennedy Trust's Chairman and MRC Professor of Immunopharmacology at the University of Southampton, said: "The MB PhD initiative combines two of the Kennedy Trust's key aims: investment into translational research and the support of early career scientists. We are delighted to build upon the fantastic programme established by the University of Oxford and we are confident that the Trust's MB PhD scheme will deliver the next generation of clinical academic leaders in musculoskeletal and inflammatory disease research.'"

More details of the Kennedy Trust announcement

How to apply for the Oxford Kennedy MB PhD (BM DPhil) Educational Training Program.

Similar stories

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).